Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any nephronophthisis in which the cause of the disease is a mutation in the ANKS6 gene.
Features include always present findings: Reduced kidney function (renal insufficiency) and Polycystic kidney dysplasia; and very common findings: Stage 5 chronic kidney disease. 12 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 5 | Stage 5 chronic kidney disease, Reduced kidney function (renal insufficiency), Nephronophthisis |
ANKS6 encodes ankyrin repeat and sterile alpha motif domain containing 6 (871 aa). Required for renal function Highest expression in Brain Cerebellum (51.5 TPM) and Brain Cerebellar Hemisphere (46.8 TPM).
Nephronophthisis 16 is caused by mutations in the ANKS6 gene on chromosome 9.
ANKS6 is classified as a druggable target with score 0.0.
Genetic testing for ANKS6 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for nephronophthisis 16 has been reported in the published literature.
Phenotype severity distribution: 2 always present features, 1 very common feature, 2 common features.
No clinical trials have been registered for nephronophthisis 16.
13 publications have been identified in PubMed for nephronophthisis 16. Research spans Case Report / Case Series (38%), Basic Science / Preclinical (23%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 38% |
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 7:35 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Heart and blood vessels |
2 |
Aortic valve stenosis, Thickened heart muscle (hypertrophic cardiomyopathy) |
Digestive system | 1 | Cholestasis |
3 |
23% |
Disease patterns and progression | 2 | 15% |
Other research | 1 | 8% |
Testing and diagnosis research | 1 | 8% |
Research summaries | 1 | 8% |
Cascio S (2026). [PMID: 42080947](https://pubmed.ncbi.nlm.nih.gov/42080947/). *Pediatr Surg Int*. [Other]
Tanaka Y (2025). [PMID: 39976632](https://pubmed.ncbi.nlm.nih.gov/39976632/). *Clin Exp Nephrol*. [Epidemiology / Natural History]
Suzuki T (2025). [PMID: 40968381](https://pubmed.ncbi.nlm.nih.gov/40968381/). *Stem Cell Res Ther*. [Basic Science / Preclinical]
Roig J (2025). [PMID: 40189576](https://pubmed.ncbi.nlm.nih.gov/40189576/). *Cell Commun Signal*. [Review / Meta-Analysis]
Matsuo T (2025). [PMID: 40503542](https://pubmed.ncbi.nlm.nih.gov/40503542/). *J Med Cases*. [Case Report / Case Series]
Pericak JM (2025). [PMID: 40642756](https://pubmed.ncbi.nlm.nih.gov/40642756/). *Case Rep Ophthalmol*. [Case Report / Case Series]
Deng K (2025). [PMID: 41378128](https://pubmed.ncbi.nlm.nih.gov/41378128/). *Front Genet*. [Basic Science / Preclinical]
Vedrine E (2025). [PMID: 40102251](https://pubmed.ncbi.nlm.nih.gov/40102251/). *Pediatr Nephrol*. [Case Report / Case Series]
Beyyumi E (2025). [PMID: 41477467](https://pubmed.ncbi.nlm.nih.gov/41477467/). *Int J Nephrol*. [Epidemiology / Natural History]
Muralidharan S (2024). [PMID: 39184759](https://pubmed.ncbi.nlm.nih.gov/39184759/). *Cureus*. [Case Report / Case Series]